| Literature DB >> 27312771 |
Nicholas B Larson1, Shannon McDonnell1, Lisa Cannon Albright2, Craig Teerlink2, Janet Stanford3, Elaine A Ostrander4, William B Isaacs5, Jianfeng Xu6, Kathleen A Cooney7,8, Ethan Lange9, Johanna Schleutker10, John D Carpten11, Isaac Powell12, Joan Bailey-Wilson13, Olivier Cussenot14, Geraldine Cancel-Tassin14, Graham Giles15,16, Robert MacInnis15,16, Christiane Maier17, Alice S Whittemore18, Chih-Lin Hsieh19, Fredrik Wiklund20, William J Catalona21, William Foulkes22,23, Diptasri Mandal24, Rosalind Eeles25, Zsofia Kote-Jarai25, Michael J Ackerman26, Timothy M Olson26, Christopher J Klein27, Stephen N Thibodeau28, Daniel J Schaid1.
Abstract
Rare variants (RVs) have been shown to be significant contributors to complex disease risk. By definition, these variants have very low minor allele frequencies and traditional single-marker methods for statistical analysis are underpowered for typical sequencing study sample sizes. Multimarker burden-type approaches attempt to identify aggregation of RVs across case-control status by analyzing relatively small partitions of the genome, such as genes. However, it is generally the case that the aggregative measure would be a mixture of causal and neutral variants, and these omnibus tests do not directly provide any indication of which RVs may be driving a given association. Recently, Bayesian variable selection approaches have been proposed to identify RV associations from a large set of RVs under consideration. Although these approaches have been shown to be powerful at detecting associations at the RV level, there are often computational limitations on the total quantity of RVs under consideration and compromises are necessary for large-scale application. Here, we propose a computationally efficient alternative formulation of this method using a probit regression approach specifically capable of simultaneously analyzing hundreds to thousands of RVs. We evaluate our approach to detect causal variation on simulated data and examine sensitivity and specificity in instances of high RV dimensionality as well as apply it to pathway-level RV analysis results from a prostate cancer (PC) risk case-control sequencing study. Finally, we discuss potential extensions and future directions of this work.Entities:
Keywords: MCMC; Next-generation sequencing; burden testing; prostate cancer
Mesh:
Year: 2016 PMID: 27312771 PMCID: PMC5063501 DOI: 10.1002/gepi.21983
Source DB: PubMed Journal: Genet Epidemiol ISSN: 0741-0395 Impact factor: 2.135